Absci Corp Stock Price, News & Analysis

Absci Corporation (NASDAQ: ABSI) reported its Q1 2025 financial results and business updates. Key highlights include: initiation of first-in-human study for ABS-101 (anti-TL1A antibody) with interim data expected in H2 2025, and promising non-human primate data for ABS-201 (anti-PRLR antibody) showing >90% bioavailability and extended half-life. The company's pipeline includes ABS-301 for immuno-oncology and ABS-501, an AI-designed anti-HER2 antibody. Financial results show revenue of $1.2M (up from $0.9M in Q1 2024), with a net loss of $26.3M. R&D expenses increased to $16.4M from $12.2M year-over-year. With $134.0M in cash and investments, Absci expects to fund operations into H1 2027.

Absci Corporation (NASDAQ: ABSI) has initiated its first Phase 1 clinical trial for ABS-101, an AI-designed anti-TL1A antibody for treating Inflammatory Bowel Disease (IBD). The trial marks Absci's transition to a clinical-stage company and will evaluate the first AI-designed biologic for IBD. The randomized, double-blind, placebo-controlled study will enroll approximately 40 healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.

ABS-101 is designed for quarterly subcutaneous dosing and demonstrates superior potency against monomeric and trimeric TL1A with reduced immunogenicity risk. Interim data is expected in the second half of 2025. Additionally, Absci is advancing ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, with Phase 1 trials planned for early 2026.

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has scheduled its first quarter 2025 earnings release and business updates for May 13, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss developments, financial results, and future outlook. Investors can access the live audio webcast through the company's investor relations website at investors.absci.com, where a replay will also be available after the event.

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in two upcoming investor conferences in April 2025:

• H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference - Fireside chat scheduled for Wednesday, April 2 at 10:30 a.m. ET / 7:30 a.m. PT
• 24th Annual Needham Virtual Healthcare Conference - Fireside chat scheduled for Tuesday, April 8 at 3:45 p.m. ET / 12:45 p.m. PT

Investors and interested parties can access both live and archived webcasts of these fireside chat sessions through Absci's investor relations website at investors.absci.com.

Absci (NASDAQ: ABSI) reported its Q4 and full year 2024 financial results, highlighting significant progress in its AI Integrated Drug Creation platform. The company secured a $20 million strategic investment from AMD and established new partnerships with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center.

Key pipeline updates include ABS-101's advancement toward Phase 1 clinical studies in H1 2025, and ABS-201's development for androgenic alopecia targeting a potential U.S. market of 80 million individuals. The company's financial position shows Q4 2024 revenue of $0.7 million and a net loss of $29.0 million. Full-year 2024 results include revenue of $4.5 million and a net loss of $103.1 million.

With $112.4 million in cash and investments as of December 31, 2024, Absci expects to fund operations into the first half of 2027.

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has scheduled the release of its fourth quarter and full year 2024 financial and operating results. The announcement will be made after market close on March 18, 2025.

The company will host a conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss business developments, financial results, and future outlook. Investors can access the live audio webcast through the company's investor relations website at investors.absci.com. A replay of the webcast will be available after the event.

Absci (Nasdaq: ABSI) has announced an inducement grant of stock options to a newly-hired non-executive employee. The grant, approved by the Compensation Committee under the 2023 Inducement Plan, includes options to purchase 162,800 shares of common stock at $3.42 per share, matching the closing price on March 3, 2025.

The stock option features a 10-year term with a four-year vesting schedule: 25% vests on the first anniversary, followed by the remaining 75% vesting in 36 approximately equal monthly installments. Full vesting will occur on the fourth anniversary, contingent on continued employment.

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. The company's management will engage in a fireside chat scheduled for Wednesday, March 19th, 2025 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Investors and interested parties can access both live and archived webcasts of the presentation through Absci's investor relations website at investors.absci.com.

Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA. The company's management will engage in a fireside chat on Monday, March 3rd at 3:10 p.m. Eastern Time (12:10 p.m. Pacific Time).

Interested parties can access both live and archived webcasts of the presentation through Absci's investor relations website at investors.absci.com.